SOURCE: The Bedford Report

The Bedford Report

September 09, 2010 12:00 ET

Analyst Research on Arena Pharmaceuticals (NASDAQ: ARNA) and Vivus (NASDAQ: VVUS) -- Biotech Overview

Note to Editors: The Following Is an Investment Opinion Being Issued by The Bedford Report.

TORONTO--(Marketwire - September 9, 2010) -  www.BedfordReport.com has released its latest newsletter providing in-depth analyst research on some of the hottest names in the Biotech industry including Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Vivus, Inc. (NASDAQ: VVUS). Register for a free membership today at www.bedfordreport.com to have complete access to this complimentary newsletter and many more.

One of the hottest trends in biotech is obesity drugs. Due to the overwhelming percentage of overweight Americans, an effective and safe weight loss drug could have astronomical earnings potential. Speculation in Vivus' product, Qnexa, and Arena's Lorcaserin has sent both companies' shares skyrocketing during the summer. However, as we learned in July from Vivus, even the slightest criticism from the FDA can send the stock plummeting straight back down. Arena will hear back from the FDA next month regarding Lorcaserin. Lorcaserin is considered the most likely anti-obesity drug to receive FDA approval due to its mild side effects.

Like you, we realize that timing is everything. We release daily market updates so you can stay ahead of the crowd and make the best investment decisions to maximize your returns. Take a few minutes to register with us for free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

The new healthcare reform bill could lead to significance ramifications for biotech companies. Over the next decade, the biotech industry is expected to lose $105 billion as result of the healthcare bill. Most argue that this will be partially offset by the additional 32 million Americans insured as a result on the bill.

For comprehensive technical analysis on Vivus and Arena, sign up today at www.bedfordreport.com.

The Bedford Report has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.bedfordreport.com/disclaimer.php

Contact Information